Retrospective analysis of the clinicopathological characteristics of gastrointestinal neuroendocrine neoplasms

Wang,Zhiqiang; Li,Wenliang; Chen,Tianxing; Yang,Jun; Luo,Lilin; Zhang,Lianyu; Sun,Baocun; Liang,Rui

doi:10.3892/etm.2015.2634

Retrospective analysis of the clinicopathological characteristics of gastrointestinal neuroendocrine neoplasms

Authors:
- Zhiqiang Wang
- Wenliang Li
- Tianxing Chen
- Jun Yang
- Lilin Luo
- Lianyu Zhang
- Baocun Sun
- Rui Liang
View Affiliations

Affiliations: Department of Oncology, The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650032, P.R. China, Department of Pathology, The First People's Hospital of Yunnan Province, Kunming, Yunnan 650032, P.R. China, Department of Pathology, The Affiliated Cancer Hospital of Tianjin Medical University, Tianjin 300060, P.R. China
Published online on: July 13, 2015 https://doi.org/10.3892/etm.2015.2634
Pages: 1084-1088

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to analyze and summarize the clinicopathological characteristics and factors affecting prognosis for patients with gastrointestinal neuroendocrine neoplasms (GINENs). Retrospective analysis was conducted on the clinicopathological data of 74 patients who were diagnosed with GINEN, and immunohistochemical methods were used to detect the expression levels of relevant markers [synaptophysin (Syn), chromogranin A (CgA) and Ki‑67]. Among the 74 cases with GINEN, there were 39 males and 35 females, with an average age of 56.9 years. There were 32 neoplasms in the rectum, 29 in the stomach, 6 in the colon, 2 in the small intestine and 5 in the appendix. All 74 cases underwent surgical resection. According to the World Health Organization Classification of Tumors of the Digestive System (2010), the diagnosis of the 74 cases showed 41 cases (55.4%) of neuroendocrine tumor (NET; 25 cases of G1 and 16 cases of G2), 21 cases (28.4%) of neuroendocrine carcinoma (NEC) and 12 cases (16.2%) of mixed adenoneuroendocrine carcinoma (MANEC). Additionally, 19 cases had metastasis to lymph nodes. During 10‑34 months of follow‑up, 15 patients had distant metastasis and 24 patients succumbed, and the accumulative survival rate in 1 or 2 years was 87.8 and 74.3%, respectively. Six factors, namely neoplasm size, depth of invasion, lymph node metastasis, distant metastasis, pathological type and the expression or lack of expression of CgA, significantly affected the survival time of patients. Definitive diagnosis of GINEN mainly relies on pathological diagnosis. GINENs with different histopathological types and grading have different clinicopathological characteristics and prognosis: NETs are mainly early lesions with a good prognosis, whereas NECs and MANECs have high malignancy and strong invasion with a worse prognosis.

View Figures

View References

1	Li CC, Xu B, Hirokawa M, Qian Z, Yoshimoto K, Horiguchi H, Tashiro T and Sano T: Alterations of E-cadherin, alpha-catenin and beta-catenin expression in neuroendocrine tumors of the gastrointestinal tract. Virchows Arch. 440:145–154. 2002. View Article : Google Scholar : PubMed/NCBI
2	Scherübl H, Streller B, Stabenow R, Herbst H, Höpfner M, Schwertner C, Steinberg J, Eick J, Ring W, Tiwari K and Zappe SM: Clinically detected gastroenteropancreatic neuroendocrine tumors are on the rise: Epidemiological changes in Germany. World J Gastroenterol. 19:9012–9019. 2013. View Article : Google Scholar : PubMed/NCBI
3	Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A and Evans DB: One hundred years after ‘carcinoid’: Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 26:3063–3072. 2008. View Article : Google Scholar : PubMed/NCBI
4	Bosman FT, Carneiro F, Hruban RH and Theise ND: World Health Organization Classification of Tumours of the Digestive System. 3. 4th. IARC Press; Lyon: 2010
5	Shebani KO, Souba WW, Finkelstein DM, Stark PC, Elgadi KM, Tanabe KK and Ott MJ: Prognosis and survival in patients with gastrointestinal tract carcinoid tumors. Ann Surg. 229:815–821. 1999. View Article : Google Scholar : PubMed/NCBI
6	Buitrago D, Trencheva K, Zarnegar R, Finnerty B, Aldailami H, Lee SW, Sonoda T, Milsom JW and Fahey TJ III: The impact of incidental identification on the stage at presentation of lower gastrointestinal carcinoids. J Am Coll Surg. 213:652–656. 2011. View Article : Google Scholar : PubMed/NCBI
7	Federspiel BH, Hansen CP, Vainer B, Hasselby JP, Bardram L and Knigge U: Incidence, pathology and clinical course and symptoms of neuroendocrine gastrointestinal tumours. Ugeskr Laeger. 172:2946–2950. 2010.(In Danish). PubMed/NCBI
8	Lawrence B, Gustafsson BI, Chan A, Svejda B, Kidd M and Modlin IM: The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am. 40:1–18. 2011. View Article : Google Scholar : PubMed/NCBI
9	Salyers WJ, Vega KJ, Munoz JC, Trotman BW and Tanev SS: Neuroendocrine tumors of the gastrointestinal tract: Case reports and literature review. World J Gastrointest Oncol. 6:301–310. 2014. View Article : Google Scholar : PubMed/NCBI
10	Maggard MA, O'Connell JB and Ko CY: Updated population-based review of carcinoid tumors. Ann Surg. 240:117–122. 2004. View Article : Google Scholar : PubMed/NCBI
11	Garcia-Carbonero R, Capdevila J, Crespo-Herrero G, DíazPérez JA, Martínez Del Prado MP, Alonso Orduña V, Sevilla-García I, Villabona-Artero C, Beguiristain-Gómez A, Llanos-Muñoz M, et al: Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): Results from the National Cancer Registry of Spain (RGETNE). Ann Oncol. 21:1794–1803. 2010. View Article : Google Scholar : PubMed/NCBI
12	Oberndorfer S: Carcinoid tumors of the duodenum. Frankfurter Zeitschrift für Pathologie. 1:426–432. 1907.(In German).
13	Williams ED and Sandler M: The classification of carcinoid tumours. Lancet. 1:238–239. 1963. View Article : Google Scholar : PubMed/NCBI
14	Hirabayashi K, Zamboni G, Nishi T, Tanaka A, Kajiwara H and Nakamura N: Histopathology of gastrointestinal neuroendocrine neoplasms. Front Oncol. 3:22013. View Article : Google Scholar : PubMed/NCBI
15	Weinstock B, Ward SC, Harpaz N, Warner RR, Itzkowitz S and Kim MK: Clinical and prognostic features of rectal neuroendocrine tumors. Neuroendocrinology. 98:180–187. 2013. View Article : Google Scholar : PubMed/NCBI
16	Landry CS, Brock G, Scoggins CR, McMasters KM and Martin RC II: Proposed staging system for colon carcinoid tumors based on an analysis of 2,459 patients. J Am Coll Surg. 207:874–881. 2008. View Article : Google Scholar : PubMed/NCBI
17	Medrano-Guzmán R, Alvarado-Cabrero I, González-Rodríguez D, López-García SC and Páez-Agraz F: Surgical prognostic factors of gastroenteropancreatic neuroendocrine tumors (GEP NET). Rev Med Inst Mex Seguro Soc. 50:243–248. 2012.(In Spanish). PubMed/NCBI
18	Lim T, Lee J, Kim JJ, Lee JK, Lee KT, Kim YH, Kim KW, Kim S, Sohn TS, Choi DW, et al: Gastroenteropancreatic neuroendocrine tumors: Incidence and treatment outcome in a single institution in Korea. Asia Pac J Clin Oncol. 7:293–299. 2011. View Article : Google Scholar : PubMed/NCBI
19	Curran T, Tulin-Silver S, Patel K, Ward S, Schneiderman M, Harpaz N, Schwartz M, Itzkowitz S, Warner RR and Kim MK: Prognostic clinicopathologic factors in longitudinally followed patients with metastatic small bowel carcinoid tumors. Pancreas. 40:1253–1257. 2011. View Article : Google Scholar : PubMed/NCBI
20	Chou WC, Hung YS, Hsu JT, Chen JS, Lu CH, Hwang TL, Rau KM, Yeh KY, Chen TC and Sun CF: Chromogranin A is a reliable biomarker for gastroenteropancreatic neuroendocrine tumors in an Asian population of patients. Neuroendocrinology. 95:344–350. 2012. View Article : Google Scholar : PubMed/NCBI
21	Chou WC, Chen JS, Hung YS, Hsu JT, Chen TC, Sun CF, Lu CH and Hwang TL: Plasma chromogranin A levels predict survival and tumor response in patients with advanced gastroenteropancreatic neuroendocrine tumors. Anticancer Res. 34:5661–5669. 2014.PubMed/NCBI
22	Knigge U and Hansen CP: Surgery for GEP-NETs. Best Pract Res Clin Gastroenterol. 26:819–831. 2012. View Article : Google Scholar : PubMed/NCBI
23	Fendrich V and Bartsch DK: Surgical treatment of gastrointestinal neuroendocrine tumors. Langenbecks Arch Surg. 396:299–311. 2011. View Article : Google Scholar : PubMed/NCBI
24	Huang LC, Poultsides GA and Norton JA: Surgical management of neuroendocrine tumors of the gastrointestinal tract. Oncology (Williston Park). 25:794–803. 2011.PubMed/NCBI
25	Ohtsuka T, Takahata S, Ueda J, Ueki T, Nagai E, Mizumoto K, Shimizu S and Tanaka M: Surgical treatment of gastroentero-pancreatic neuroendocrine tumor. Gan To Kagaku Ryoho. 40:843–846. 2013.(In Japanese). PubMed/NCBI
26	Gaujoux S, Sauvanet A and Belghiti J: Place of surgical resection in the treatment strategy of gastrointestinal neuroendocrine tumors. Target Oncol. 7:153–159. 2012. View Article : Google Scholar : PubMed/NCBI
27	Scherübl H, Jensen RT, Cadiot G, Stölzel U and Klöppel G: Management of early gastrointestinal neuroendocrine neoplasms. World J Gastrointest Endosc. 3:133–139. 2011. View Article : Google Scholar : PubMed/NCBI
28	Pavel ME, Hainsworth JD, Baudin E, Peeters M, Hörsch D, Winkler RE, Klimovsky J, Lebwohl D, Jehl V, Wolin EM, et al: RADIANT-2 Study Group: Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): A randomised, placebo-controlled, phase 3 study. Lancet. 378:2005–2012. 2011. View Article : Google Scholar : PubMed/NCBI
29	Reidy DL, Tang LH and Saltz LB: Treatment of advanced disease in patients with well-differentiated neuroendocrine tumors. Nat Clin Pract Oncol. 6:143–152. 2009. View Article : Google Scholar : PubMed/NCBI
30	Khasraw M, Yap SY and Ananda S: Neuroendocrine neoplasms of the GI tract: The role of cytotoxic chemotherapy. Expert Rev Anticancer Ther. 13:451–459. 2013. View Article : Google Scholar : PubMed/NCBI
31	Castellano D, Bajetta E, Panneerselvam A, Saletan S, Kocha W, O'Dorisio T, Anthony LB and Hobday T: RADIANT-2 Study Group: Everolimus plus octreotide long-acting repeatable in patients with colorectal neuroendocrine tumors: A subgroup analysis of the phase III RADIANT-2 study. Oncologist. 18:46–53. 2013. View Article : Google Scholar : PubMed/NCBI